Effects of radioiodine on thyrotrophin binding inhibiting immunoglobulins in Graves' disease. 1979

A M McGregor, and M M Petersen, and R Capiferri, and D C Evered, and B R Smith, and R Hall

We have studied the effects of 131I therapy on thyrotrophin binding inhibiting immunoglobulins (TBII) in fifty-five patients with Graves' disease and five patients with toxic multinodular goitre (MNG). A group of forty patients with Graves' disease and four patients with toxic MNG were treated with drugs and acted as controls. In 78% of patients treated with 131I there was a marked increase in the serum TBII activity during the 3 months following therapy, whereas drug-treated patient showed a decrease (77%) or no change in TBII activity over the same period. TBII activity was not detectable in patients with toxic MNG before or after drug or 131I therapy. Consideration of the mechanisms involved in the changes in serum TBII activity after 131I treatment or during drug treatment provide insight into the basic defects responsible for the development of hyperthyroid Graves' disease and suggest that both the thyroid and immune system are involved.

UI MeSH Term Description Entries
D007136 Immunoglobulins Multi-subunit proteins which function in IMMUNITY. They are produced by B LYMPHOCYTES from the IMMUNOGLOBULIN GENES. They are comprised of two heavy (IMMUNOGLOBULIN HEAVY CHAINS) and two light chains (IMMUNOGLOBULIN LIGHT CHAINS) with additional ancillary polypeptide chains depending on their isoforms. The variety of isoforms include monomeric or polymeric forms, and transmembrane forms (B-CELL ANTIGEN RECEPTORS) or secreted forms (ANTIBODIES). They are divided by the amino acid sequence of their heavy chains into five classes (IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M) and various subclasses. Globulins, Immune,Immune Globulin,Immune Globulins,Immunoglobulin,Globulin, Immune
D007457 Iodine Radioisotopes Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes. Radioisotopes, Iodine
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D005260 Female Females
D006044 Goiter, Nodular An enlarged THYROID GLAND containing multiple nodules (THYROID NODULE), usually resulting from recurrent thyroid HYPERPLASIA and involution over many years to produce the irregular enlargement. Multinodular goiters may be nontoxic or may induce THYROTOXICOSIS. Nodular Goiter,Goiters, Nodular,Nodular Goiters
D006111 Graves Disease A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes (GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy). Basedow's Disease,Exophthalmic Goiter,Goiter, Exophthalmic,Graves' Disease,Basedow Disease,Hyperthyroidism, Autoimmune,Basedows Disease,Disease, Basedow,Disease, Basedow's,Disease, Graves,Disease, Graves',Exophthalmic Goiters,Goiters, Exophthalmic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013961 Thyroid Gland A highly vascularized endocrine gland consisting of two lobes joined by a thin band of tissue with one lobe on each side of the TRACHEA. It secretes THYROID HORMONES from the follicular cells and CALCITONIN from the parafollicular cells thereby regulating METABOLISM and CALCIUM level in blood, respectively. Thyroid,Gland, Thyroid,Glands, Thyroid,Thyroid Glands,Thyroids

Related Publications

A M McGregor, and M M Petersen, and R Capiferri, and D C Evered, and B R Smith, and R Hall
May 1995, Clinical endocrinology,
A M McGregor, and M M Petersen, and R Capiferri, and D C Evered, and B R Smith, and R Hall
January 1983, Acta endocrinologica. Supplementum,
A M McGregor, and M M Petersen, and R Capiferri, and D C Evered, and B R Smith, and R Hall
August 1981, Australian and New Zealand journal of medicine,
A M McGregor, and M M Petersen, and R Capiferri, and D C Evered, and B R Smith, and R Hall
May 1986, Clinical and experimental immunology,
A M McGregor, and M M Petersen, and R Capiferri, and D C Evered, and B R Smith, and R Hall
February 1980, Clinical endocrinology,
A M McGregor, and M M Petersen, and R Capiferri, and D C Evered, and B R Smith, and R Hall
August 1981, Clinical endocrinology,
A M McGregor, and M M Petersen, and R Capiferri, and D C Evered, and B R Smith, and R Hall
October 1982, Clinical endocrinology,
A M McGregor, and M M Petersen, and R Capiferri, and D C Evered, and B R Smith, and R Hall
January 1987, The Korean journal of internal medicine,
A M McGregor, and M M Petersen, and R Capiferri, and D C Evered, and B R Smith, and R Hall
August 1994, Journal of molecular endocrinology,
A M McGregor, and M M Petersen, and R Capiferri, and D C Evered, and B R Smith, and R Hall
June 1982, Clinical endocrinology,
Copied contents to your clipboard!